This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Zalutumumab

Genmab A/S

Drug Names(s): HuMax-EGFr

Description: HuMax-EGFr is a fully human antibody targeting the Epidermal Growth Factorreceptor, or EGFr. EGFr is a receptor molecule that has been found in excess on many tumor cells, including carcinoma of the head and neck, breast, colon, prostate, lung and ovary.

Deal Structure: Medarex received an equity interest in Genmab in exchange for a license of its proprietary antibody technology. It is not entitled to license fees, milestone payments or royalties from the license of this particular product candidate (zalutumumab).

In July 2009, Bristol-Myers Squibb and Medarex announced that the companies signed a definitive merger agreement providing for the acquisition of Medarex by Bristol-Myers Squibb, for $16.00 per share in cash.

In September 2009, Bristol-Myers Squibb completed its acquisition of Medarex.

Partners: Bristol-Myers Squibb Company


Zalutumumab News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug